ClinicalTrials.gg
CompletedNCT06451640Updated Nov 20, 2025

A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps

A Phase 2 interventional study of 210mg of TQC2731 injection and 420mg of TQC2731 injection in Chronic Rhinosinusitis With Nasal Polyps, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Completed at 16 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies in Nasal Polyps with a site in China — 17 open to participants now, 24 under way, 7 of them phase 3. Nasal Polyps · China.

Enrollment
30th of 43
59 · median 90
Started
2024
with 5 others
Phase 2
13 of 46
4 open now
Registered
26th of 46
by date

Among the 46 studies in Nasal Polyps with a site in China, this one is the 30th largest by enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2024, is one of 13 in phase 2, and was the 26th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

17 of the 46 studies in Nasal Polyps with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Nasal Polyps with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of TQC2731 injection in the treatment of chronic sinusitis with nasal polyps.

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects sign before study, fully understand the purpose, procedures and possible adverse reactions of the study;
  • Male and female, ≥18 years old;
  • Participate in the clinical study of TQC2731 for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) (study number TQC2731-II-02) and meet the following criteria "a" or "b": a. Participants complete the prescribed treatment according to the protocol requirements and complete end of treatment (EOT) visits; b. The subject withdrew early due to poor compliance or other objective reasons other than TQC2731 related adverse events (AEs), and completed the early withdrawal visit according to the plan. After evaluation by the researcher and sponsor, the factors that led to the subject's early termination of the main study treatment have disappeared/no longer affect the subject's participation in this continuing study;
  • Subjects used steady dose of intranasal (INCS) over 4 weeks before screening (subjects willing to use Mometasone Furoate Aqueous Nasal Spray (MFNS) while studying);
  • Subjects agree from sign informed consent to last administration over 6 mouth without Family planning,and take effective non-pharmaceutical .

Exclusion criteria

Exclusion Criteria:

  • In the main study (TQC2731-II-02), SAE related to TQC2731 occurred, or TQC2731 treatment was terminated due to AE related to TQC2731. After discussion between the investigator and the sponsor, it was determined that the subject was not suitable to continue receiving TQC2731 treatment;
  • The subjects had poor compliance in the main study and were deemed unable to complete this continuing study by the researchers;
  • During the main study (TQC2731-II-02), any serious progression or poorly controlled comorbidities were found (such as asthma exacerbation requiring adjustment of background medication), and the main investigator determined that the subject was not suitable to participate in the trial;
  • Presence of conditions/concomitant diseases that affect the evaluation of efficacy, e.g.

    1. Posterior nostril polyps;
    2. Imaging suspected or confirmed fungal sinusitis;
    3. Nasal polyp score(NPS) cannot be evaluated due to nasal surgery to alter the structure of the lateral nasal wall;
    4. Subjects with nasal and benign tumors (papilloma, blood furuncle, etc.).
  • Any type of active malignancy or a history of malignancy (Patient with basal cell carcinoma, skin localized squamous cell carcinoma or carcinoma in situ of cervix, if curative treatment was completed for more than 12 months prior to visit 1 can join the study; Other malignant tumors can join the study if patients had completed curative therapy for at least 5 years prior to visit 1);
  • Active disease;
  • Known or suspected history of , immune dysfunction, or immune dysfunction, including but not limited to invasive opportunistic infections, even if the infection has subsided;
  • Uncontrolled epistaxis occurred within 2 months before screening;
  • Infection requiring treatment with systemic antibacterial, antiviral, antifungal, antiparasitic, or antiparasitic agents occurred within 14 days before screening;
  • Helminth parasite infection was diagnosed within 24 weeks prior to screening and had not received or failed to respond to standard treatment;
  • Leukotriene antagonists/modulators were used while screening(using a stable dose of leukotriene modulator for ≥30 days before screening was accepted);
  • Regular use of decongestants (topical or systemic) before screening, short-term use for endoscopy excepted;
  • Patients who received any of the following treatments before screening:

    1. Immunosuppressive therapy had been administered within the previous 8 weeks or five half-lives (whichever was longer), (including but not limited to cyclophosphamide, cyclosporine, interferon-γ, azathioprine, methotrexate, mycophenolate mofetil and tacrolimus, etc.);
    2. Monoclonal antibody therapy had been administered within the previous 8 weeks or five half-lives (whichever was longer), (Including but not limited to: benralizumab, mepolizumab, omalizumab, resveratrol, dupilumab, etc.);
    3. Systemic were used during the first 28 days;
    4. Glucocorticoid-eluting nasal stents were used during the first 6 mouths;
    5. Immune globulin or blood products therapy were used during the first 28 days; 6) was administered for the first 28 days or during the planned study period; 7)Received allergen specific immunotherapy 6 mouth before screening(if being treated at a stable dose and not expected to change during study,3 mouth before screening and 1 mouth before visit 1 were accepted); 8)Join any other study within 3 mouths.
  • Patients with concomitant asthma begin inhaled corticosteroid therapy within the first 4 weeks of the screening period (For patients who have been assessed to maintain a stable dose for at least 4 weeks prior to screening and whose dose has been maintained throughout the entire study period, inhaled corticosteroids can be administered at a dose of ≤ 1000μ Fluticasone propionate or equivalent doses of other inhaled corticosteroids.);
  • Any infectious disease screening indicator that meets the following criteria during screening:

    1. Active tuberculosis infection during screening;
    2. virus surface antigen (HBsAg) positive, or hepatitis B core antibody (HBcAb) positive and hepatitis B virus (HBV) DNA positive;
    3. Anti- virus (Anti-HCV) positive and Hepatitis C virus ribonucleic acid (HCV-RNA) positive;
    4. Positive Treponema pallidum antibody (Anti TP) (if the Treponema pallidum serological test is positive, further non treponema pallidum serological tests will be conducted, the latter being negative and judged by the researcher as a patient who has previously been infected with syphilis but has been cured and meets the inclusion criteria);
    5. Positive for antibodies (Anti HIV);
  • Abnormal laboratory test results:

    1. (AST)>2.5 x value (ULN);
    2. Alanine aminotransferase (ALT)>2.5 x upper limit of normal value (ULN);
    3. Creatinine>1.5 x ULN.
  • Pregnant or lactating women;
  • A history of or allergic reaction to Mometasone furoate nasal spray (Nasonex ®) or any component of TQC2731 injection;
  • A history of systemic allergy to any biologic drug(except local injection site reactions);
  • The subjects had poor compliance and were judged unable to complete the study;
  • Any abnormal findings, including physical examination, vital signs, 12-lead , blood biochemistry, blood routine or urine routine, and the researcher's judgment that participating in the trial may put the patient at risk, or may affect the study results or hinder the patient's ability to complete the entire study process.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    210mg of TQC2731 injection

    210mg of TQC2731 injection combined with Mometasone Furoate Aqueous Nasal Spray, 28days as a treatment cycle.

    Drug: 210mg of TQC2731 injection

  • Experimental
    420mg of TQC2731 injection

    420mg of TQC2731 injection combined with Mometasone Furoate Aqueous Nasal Spray, 28days as a treatment cycle.

    Drug: 420mg of TQC2731 injection

Interventions

  • Drug210mg of TQC2731 injection

    TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.

  • Drug420mg of TQC2731 injection

    TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.

06

What researchers measure

Primary outcomes

  1. Treatment-related adverse event rate

    The frequency of treatment-related adverse events (TEAEs) occurring during treatment at each evaluation time point.

    Time frame: Up to thirty six weeks

Secondary outcomes

  1. Treatment-related serious adverse events rate

    The frequency of serious adverse events (SAEs) occurring during treatment at each evaluation time point.

    Time frame: Up to thirty six weeks

  2. Abnormal laboratory test indicators

    The number and severity of abnormal laboratory test indicators.

    Time frame: Up to thirty six weeks

  3. Nasal Polyp Score (NPS)

    NPS is the sum of the left and right nostril scores evaluated through nasal endoscopy, with a total score range of 0 to 8. NPS is based on polyp grading, with a score of 0-4 based on polyp grading.

    Time frame: Baseline up to thirty six weeks

  4. Nasal congestion score (NCS)

    NCS is determined by the subjects based on the severity of the nasal congestion in the past 24 hours. This score uses a 0-3 classification scale, where 0=no symptoms, 1=mild symptoms, 2=moderate symptoms, and 3=severe symptoms.

    Time frame: Baseline up to thirty six weeks

  5. Anosmia score

    Anosmia Score is evaluated by subjects based on their severity of Anosmia on the day. This score uses a 0-3 classification scale, where 0=no symptoms, 1=mild symptoms, 2=moderate symptoms, and 3=severe symptoms.

    Time frame: Baseline up to thirty six weeks

  6. Total symptom score (TSS)

    TSS is the sum of nasal congestion, anosmia, and rhinorrhea (the average of anterior and posterior rhinorrhea), with a score range of 0-9 points. The severity is evaluated by the subject and recorded on the subject diary record card.

    Time frame: Baseline up to thirty six weeks

  7. Visual analogue scale (VAS) for sinusitis

    VAS for sinusitis is a questionnaire that subjective evaluation of the overall severity of sinusitis by subjects, with a score range of 0-10 points. The higher the score, the greater the impact of sinusitis on the quality of life of the subjects.

    Time frame: Baseline up to thirty six weeks

  8. Lund Mackay (LMK) score

    The LMK score is based on the results of sinus Computed Tomography (CT) scans. Evaluated by researchers, divided into left and right sinus systems, with 0-12 points per side and a total score of 0-24 points.

    Time frame: Baseline up to twenty eight weeks

  9. Immunogenicity-anti-drug antibody

    Incidence and their titers of Anti-drug antibody (ADA).

    Time frame: 1 hour on day 1 before administration, day 197, day 253 during withdrawal

  10. Immunogenicity-neutralizing antibody

    Incidence of neutralizing antibody (Nab).

    Time frame: 1 hour on day 1 before administration, day 197, day 253 during withdrawal

07

Study locations

16 sites
  • Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou 563000, China
  • Cangzhou Central Hospital
    Cangzhou, Hebei 061017, China
  • Jingzhou Central Hospital
    Jingzhou, Hubei 434020, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
  • The First Affiliated Hospital of Suzhou University
    Suzhou, Jiangsu 215000, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221000, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330000, China
  • Affiliated Zhongshan Hospital Of Dalian university
    Dalian, Liaoning 116001, China
  • The First Affiliated Hospital of Xi'an Jiao Tong University
    Xi'an, Shaanxi 710000, China
  • The Afiliated Hospital Of QINGDAO University
    Qingdao, Shandong 266071, China
  • Eye&Ent Hospital of Fudan University
    Shanghai, Shanghai Municipality 20031, China
  • ChengDu Second People's Hospital
    Chengdu, Sichuan 610021, China
  • West China Hospital
    Chengdu, Sichuan 610041, China
  • Hospital of Chengdu University of TCM
    Chengdu, Sichuan 610072, China
  • Tianjin People's Hospital
    Tianjin, Tianjin Municipality 300122, China
  • The First Affiliated Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang 830000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Oct 2025, 15 months.

Of 24 phase 2 interventional studies under Nasal Polyps, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 32. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Jun 11, 2024
StartActual
Jul 4, 2024
Primary completionActual
Oct 17, 2025
CompletionActual
Oct 17, 2025
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06451640
Responsible party
Sponsor
First posted
Jun 11, 2024
Start date
Jul 4, 2024
Primary completion
Oct 17, 2025
Completion
Oct 17, 2025
Last update
Nov 20, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion